PTGX · Protagonist Therapeutics, Inc.

The thesis

Protagonist Therapeutics has two approved drugs that carry royalties and has now received $275 million from Takeda, but royalties remain unseen in its reported results. The case stands on that cash and those contracts until the third-quarter Form 10-Q, Johnson & Johnson's (J&J) January report and Protagonist's own fourth-quarter report show actual royalty income.

The 5 November 2026 report beat estimates on milestone accounting. Revenue was $274.4 million, of which $266.6 million was recognition of the $275 million Takeda payments (company release). Benzinga put the consensus at $238.47 million in revenue and $2.55 in earnings per share, against reported $3.07 diluted.

The narrative is maturing: both approvals are well known, and the 5 November 2026 report added no commercial sales figure for either drug. A daily close below $122 would end the case.

Bullish and bearish views on Protagonist Therapeutics, Inc.

The bull case on Protagonist Therapeutics, Inc. (PTGX), in brief: The Takeda cash has arrived. The bear case: Royalties are small or absent so far.

Bull case

• The Takeda cash has arrived. The company said on 5 November 2026 that the $200 million opt-out fee and $75 million approval milestone were received in October 2026. That cash comes on top of the $834.6 million in cash and marketable securities reported at 30 September 2026.
• Royalty contracts are large. The 5 November 2026 release sets MIMRYLO royalties at 14–29%, about 21% on average at $1.5 billion of annual sales. ICOTYDE royalties run 6–10%, about 7.25% on average at $4 billion of annual sales.
• ICOTYDE is reaching more markets. The company reported psoriasis approvals in China, Japan and the European Union during the third quarter of 2026. Up to $580 million of ICOTYDE milestones and up to $875 million of MIMRYLO milestones remain available (release, 5 November 2026).
• Analyst targets sit above the price. Investing.com reported on 4 November 2026, before the results, that all 14 covering analysts rate the shares a buy, with a mean target of $178.57. UBS's target is $184, Leerink Partners' $190 and TD Cowen's $160 (Benzinga, October 2026).
• Profit and a repurchase authorization. Net income was $220.0 million in the third quarter of 2026, against a $39.3 million loss a year earlier. The board authorized up to $300 million of repurchases on 8 September 2026.
• The owned pipeline has dated starts. The company plans a Phase 2b psoriasis study of PN-881, its oral IL-17 antagonist, in early Q1 2027. It plans Phase 1 for PN-8047, an oral polycythemia vera candidate, in Q1 2027.

Bear case

• Royalties are small or absent so far. Only $7.8 million of third-quarter revenue came from anything other than the Takeda recognition, and the release attributes it to development services and other revenue. Any ICOTYDE royalty booked in the second full quarter of US sales therefore sits inside that figure.
• Partner sales remain hidden. The 5 November 2026 release gives no ICOTYDE or MIMRYLO sales figure. J&J's 13 October 2026 release credits "new products within Other Immunology" and gives no standalone ICOTYDE number in the sources reviewed.
• Headline earnings will not repeat automatically. The third-quarter profit rests on a one-time $275 million trigger, and deferred revenue stood at only $16.3 million at 30 September 2026. Research spending was $41.3 million, and the company expects it to rise over the rest of 2026.
• A rival has strong trial results. Silence Therapeutics reported on 10 August 2026 that divesiran produced an 88% clinical response versus 19% for placebo in polycythemia vera, MIMRYLO's approved disease.
• With 14 of 14 analysts already positive (Investing.com, 4 November 2026), few upgrades remain available.
• No repurchases are reported. The 5 November 2026 release reports no purchases under the $300 million authorization and ties timing to market conditions.

Price setup

The adjusted daily close on 5 November 2026 was $135.26, which is 14.7% below the 52-week high of $158.62. The shares fell 9.8% over three months.

The 14-day relative strength index, a 0–100 momentum gauge, reads 59.1, a neutral level.

The $122 invalidation level sits just under the 200-day moving average of $122.07 as of 2 October 2026. The earnings date has now passed, and no post-report analyst target changes had surfaced by 6 November 2026.

Catalysts, next 30 days

• ~9 November 2026, est.: third-quarter Form 10-Q. It had not surfaced in a search on 6 November 2026. It is the first place a royalty amount, royalties receivable or repurchases could be stated.
• ~January 2027, est.: J&J fourth-quarter report. A standalone ICOTYDE figure would allow the royalty to be sized for the first time.

Elapsed catalysts

• November 2026, dates not stated: four investment bank conferences, announced 27 October 2026. The earnings release mentions no call, so these are the next public settings for management comment on launches and the buyback. (passed 10d ago)
• Early Q1 2027: PN-881 Phase 2b start, per the company's 5 November 2026 guidance. (passed 1d ago)
• ~February 2027, est.: Protagonist fourth-quarter report. This is the first quarter with a full three months of MIMRYLO sales, following approval announced on 28 August 2026. (passed 70d ago)

What would change the view

The case breaks if partner launches disappoint. The clearest evidence would be J&J or Takeda reporting launch sales clearly below expectations, or Protagonist's filings still showing negligible royalties in the fourth quarter of 2026. Physician or regulatory progress that moves divesiran ahead of MIMRYLO in polycythemia vera would also weaken it.

The next filing or report showing no repurchases would remove one support, though not the royalty case. On price, a daily close below $122 would end the thesis.

The case strengthens if a filing or partner report gives a royalty or sales figure that supports the analyst targets above, or if the company reports actual repurchases.

What it trades with

Protagonist's royalty income depends on two partners, so J&J and Takeda reports are the closest read-across for its results. J&J's total company numbers carry little information here: third-quarter 2026 sales of about $25.4 billion grew 5.9% (J&J, 13 October 2026) with ICOTYDE not broken out in the sources reviewed.

Silence Therapeutics' divesiran news bears directly on the polycythemia vera part of the case. Oral psoriasis competition affects the ICOTYDE part.